There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SAGE Therapeutics (NASDAQ: SAGE) and Zynerba Pharmaceuticals (NASDAQ: ZYNE) with bullish sentiments.
SAGE Therapeutics (NASDAQ: SAGE)
“After receipt of FDA meeting minutes, SAGE announced its current ‘547 PPD trials.”
According to TipRanks.com, Baral is a 3-star analyst with an average return of 1.8% and a 36.0% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Protalix Biotherapeutics, and Intra-Cellular Therapies.
SAGE Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $60.33.
Zynerba Pharmaceuticals (NASDAQ: ZYNE)
“We continue to believe that ZYN002’s safety profile compares favorably to GWPH’s orally administered botanical CBD product Epidiolex.”
According to TipRanks.com, Lee is a 1-star analyst with an average return of -2.3% and a 42.4% success rate. Lee covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Actinium Pharmaceuticals, and Asterias Biotherapeutics.
Zynerba Pharmaceuticals has an analyst consensus of Strong Buy.